20
Aug

Amicus Therapeutics has come a long way in two years, shaking off a clinical misstep on the way to a second Phase III success for its rare disease treatment. Now the biotech is preparing to make its case to regulators, hoping to win approval for a new approach to Fabry disease.

…read more

Source: Amicus sets sights on approval as rare disease pill clears Phase III

    

0 No comments